Bioequivalence Study of Two Imiquimod Cream 5%
Public ClinicalTrials.gov record NCT00828568. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Study identification
- NCT ID
- NCT00828568
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Enrollment
- 425 participants
Conditions and interventions
Conditions
Interventions
- Imiquimod 5% manufactured by Taro Drug
- Aldara - Imiquimod 5% Drug
- Imiquimod Vehicle manufactured by Taro Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Feb 28, 2009
- Completion
- Apr 30, 2009
- Last update posted
- Jan 27, 2014
2008 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site | Gilbert | Arizona | — | — |
| Investigator Site | Tempe | Arizona | — | — |
| Investigator Site | Tuscon | Arizona | — | — |
| Investigator Site | Denver | Colorado | — | — |
| Investigator Site | Jacksonville | Florida | — | — |
| Investigator Site | Miami | Florida | — | — |
| Investigator Site | Evansvill | Indiana | — | — |
| Investigator Site | Plainfield | Indiana | — | — |
| Investigator Site | Olathe | Kansas | — | — |
| Investigator Site | Wichita | Kansas | — | — |
| Investigator Site | Omaha | Nebraska | — | — |
| Investigator Site | Henderson | Nevada | — | — |
| Investigator Site | Cary | North Carolina | — | — |
| Investigator Site | Hickory | North Carolina | — | — |
| Investigator Site | High Point | North Carolina | — | — |
| Investigator Site | Winston-Salem | North Carolina | — | — |
| Investigator Site | Simpsonville | South Carolina | — | — |
| Investigator Site | Murfreesboro | Tennessee | — | — |
| Investigator Site | College Station | Texas | — | — |
| Investigator Site | Tyler | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00828568, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00828568 live on ClinicalTrials.gov.